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Abstract
Haploinsufficiency of TCF4 causes Pitt-Hopkins syndrome (PTHS): a severe form of mental retardation with
phenotypic similarities to Angelman, Mowat-Wilson and Rett syndromes. Genome-wide association studies have also
found that common variants in TCF4 are associated with an increased risk of schizophrenia. Although TCF4 is
transcription factor, little is known about TCF4-regulated processes in the brain. In this study we used genome-wide
expression profiling to determine the effects of acute TCF4 knockdown on gene expression in SH-SY5Y
neuroblastoma cells. We identified 1204 gene expression changes (494 upregulated, 710 downregulated) in TCF4
knockdown cells. Pathway and enrichment analysis on the differentially expressed genes in TCF4-knockdown cells
identified an over-representation of genes involved in TGF-β signaling, epithelial to mesenchymal transition (EMT)
and apoptosis. Among the most significantly differentially expressed genes were the EMT regulators, SNAI2 and
DEC1 and the proneural genes, NEUROG2 and ASCL1. Altered expression of several mental retardation genes such
as UBE3A (Angelman Syndrome), ZEB2 (Mowat-Wilson Syndrome) and MEF2C was also found in TCF4-depleted
cells. These data suggest that TCF4 regulates a number of convergent signaling pathways involved in cell
differentiation and survival in addition to a subset of clinically important mental retardation genes.
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Introduction
Transcription factor 4 (TCF4) is a basic helix-loop-helix
(bHLH) transcription factor involved in neurodevelopment and
dendritic cell diversification in the immune system [1–5].
Mounting genetic and biological evidence supports a crucial
role for TCF4 in healthy brain function. Mutations in TCF4
cause Pitt-Hopkins syndrome (PTHS); a severe mental
retardation syndrome associated with a facial gestalt, breathing
abnormalities, visual problems, delayed speech development
and seizures [6–8]. PTHS is caused by deletions, nonsense
and missense mutations in the TCF4 gene on human
chromosome 18, resulting in haploinsufficiency [6–9]. The
majority of TCF4 missense mutations cluster in the bHLH
domain of the protein where they attenuate transcription and
can impair protein–protein interactions [6,8,10–12]. In addition
to PTHS, balanced chromosomal abnormalities disrupting
TCF4 and copy number variants have been found in patients
with autism and neurodevelopmental disorders that were
previously undiagnosed with PTHS [13].
In addition to rare mutations, common variants (single
nucleotide polymorphisms, SNP) in TCF4 are associated with
an increased risk of schizophrenia [14,15]. Genome-wide
association studies found that a SNP (rs9960767) located in
intron 3 of TCF4 was associated with schizophrenia (P = 4.1 x
10-9), surpassing the statistical threshold for genome-wide
significance [14,15]. Additional TCF4 variants have also been
associated with schizophrenia providing further support for
TCF4 as a schizophrenia risk gene [1]. Interestingly, the
rs9960767 risk allele is correlated with impaired sensorimotor
gating and cognitive performance, mirroring established
schizophrenia endophenotypes [16,17]. Recently, Wirgenes
and colleagues found that psychosis was associated with
elevated TCF4 transcript levels and that TCF4 risk variants
were associated with a range of clinical, cognitive and brain
morphological abnormalities [18]. Multiple alternatively spliced
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TCF4 isoforms have been described, however the role of the
different spliced forms on transcription has not been
extensively studied [19,20]. It is therefore possible that SNPs
associated with schizophrenia may differentially regulate the
expression of one or more TCF4 isoforms leading to subtle
changes in critical neurodevelopmental pathways.
TCF4, TCF12 (HEB), TCF3 (E2A) form the class I bHLH
transcription factors in humans [21]. TCF4 interacts with a
potentially large repertoire of transcription factors including the
products of proneural genes such as ASCL1, ATOH1 and
NEUROD1 to regulate neurogenesis and cell type specification
in the developing brain [5,15,22,23]. ASCL1, ATOH1 and
NEUROD1 are bHLH transcription factors that form obligatory
heterodimers with TCF4 (and other E-proteins) to regulate
gene expression at E-box containing promoters. Heterodimers
bind directly to E-boxes that have the consensus sequence
“CANNTG” allowing them to regulate gene expression.
Additionally, the structurally related ID (inhibitors of
differentiation) proteins such as ID2, are dominant-negative
regulators of TCF4. ID proteins form inactive heterodimers with
TCF4 preventing the sequestered protein from binding E-boxes
or interacting with other transcriptional activators thereby
maintaining cells in an undifferentiated state. During
neurodevelopment, the balance of E-proteins, proneural and ID
proteins in a cell are therefore an important regulatory step in
determining cell fate [24].
The role of TCF4 in brain development and behavior has
also been studied in mouse models. Homozygous Tcf4
knockout mice do not survive past birth and although gross
brain structure and size does not seem to be affected, there
are specific regions of the pontine nucleus where cells fail to
migrate to their correct positions [5]. Furthermore, adult mice
moderately over-expressing TCF4 in the brain have
behavioural abnormalities including deficits in sensory-motor
gating and cognitive performance, reminiscent of certain
schizophrenia endophenotypes [22].
Although TCF4 has been studied in the context of
neurodevelopment and behavior, very little is known about
TCF4 regulated genes and processes in the developing and
adult nervous system. In this study we use small interfering
RNA (siRNA) to acutely knockdown TCF4 in the SH-SY5Y
neuronal cell line. Using microarrays and conservative pathway
analysis we find that TCF4 knockdown is associated with
robust gene expression changes in multiple, convergent
signaling pathways.
Results
Knockdown of TCF4 in SH-SY5Y cells
To determine the effects of TCF4 depletion on gene
expression in a cell line of neuronal origin, we tested a series of
siRNA duplexes for their efficacy in knocking down TCF4 in
SH-SY5Y cells. SH-SY5Y cells were chosen because they
express high levels of TCF4 and can be efficiently transfected
with single siRNA duplexes to achieve a robust knockdown.
Quantitative PCR (qPCR) and quantitative western blots were
used to test the efficacy of each duplex to knockdown TCF4.
qPCR analysis of each knockdown showed that KD1 (exon 12)
caused an 80% reduction of the TCF4 transcript whereas KD2
(exon 19) reduced TCF4 expression by 62% compared to
mock transfected cells (Figure 1A). Importantly, siRNAs
targeting GAPDH (exons 1 and 2) and mock transfection had
no significant effect on the level of the TCF4 transcript (Figure
1A). Reduced levels of the TCF4 protein was also verified by
quantitative western blotting (Figure 1B and 1C). Knockdown of
TCF4 with TCF4 KD1 and KD2 resulted in a greater than 80%
reduction in proteins levels with both duplexes. KD2 was less
effective than KD1 at knocking down the TCF4 protein
reflecting the qPCR data.
Microarray analysis of TCF4 knockdown
RNA prepared from siRNA-treated cells was converted to
cDNA, labeled and hybridized to a Toray microarray for
genome-wide transcript analysis. Two control groups, mock
transfected and GAPDH siRNA transfected, were used for
background correction. The GAPDH siRNA control was used
because it has minimal off-target effects and is able to activate
the RNA-induced silencing complex (RISC). Since TCF4 KD1
produced more gene expression changes than knockdown with
TCF4 KD2 (overlap 79%) both treatment groups were
combined in the ANOVA. A one-way ANOVA comparing the
control (mock and GAPDH) and TCF4 (TCF4 KD1 and KD2)
knockdown groups was used to identify differentially expressed
genes in TCF4-depleted cells. Gene expression changes
clustered with the experimental treatment indicating that each
siRNA had a distinct but overlapping gene expression
signature (Figure S1). A false discovery rate (FDR) of 0.01 was
used to generate a high confidence list of 1204 differentially
expressed genes (494 upregulated, 710 downregulated). The
top 40 up- and downregulated genes ranked by fold change
are illustrated in Figure 2A. Initial examination of the most
robust gene expression changes in TCF4-knockdown cells
(Figure 2A) appeared to suggest a role for TCF4 in apoptosis
or inflammasome function (up-regulation of CASP1 and
CASP4), cell signaling (down-regulation of IGF2, BMP7 and
LEFTY1) and neurodevelopment (down-regulation of
NEUROG2, ASCL1 and MEF2C). Furthermore, several of the
major gene expression changes in TCF4-knockdown cells
involved transcription factors including ASCL1 and NEUROG2
that interact directly with TCF4 at E-boxes [6,10,11,25]. Finally,
a number of imprinted genes, IGF2, H19 and CDKN1C were
prominent amongst the most significantly downregulated genes
in TCF4-knockdown cells (Figure 2A).
qPCR was used to independently validate the gene
expression changes detected on the microarray. We selected 5
up- (FAS, NTRK1, CASP8, NOTCH1, CASP1) and 5 down-
regulated genes (IGF2, CDKN1C, NEUROG2, BMP7, CDK6)
that had a fold change above or below 1.5. The genes were
also selected on the basis of their known importance to
developmental processes and their recurrent appearance in the
downstream enrichment analyses (see below). Transcript
abundance was measured from the same RNA samples used
on the microarray, allowing a direct comparison of the inferred
changes. Each of the 10 genes was confirmed as differentially
expressed by qPCR and had similar fold changes to that
detected in the microarray (Table 1).
Microarray Analysis of TCF4-Depleted Cells
PLOS ONE | www.plosone.org 2 August 2013 | Volume 8 | Issue 8 | e73169
Figure 1.  siRNA-mediated knockdown of TCF4 in SH-SY5Y
cells.  SH-SY5Y cells were transfected with siRNA
oligonucleotides targeting TCF4 (KD1 and KD2) or GAPDH.
After 72h, RNA and protein were extracted to assess the
knockdown efficiency. (A) Primers complimentary to a
constitutive exon present in all TCF4 isoforms (exon 13) were
used to measure overall transcript abundance by qPCR in
three biological replicates. TCF4 knockdown efficiency was
similar with both KD1 and KD2 whereas the control GAPDH KD
did not affect TCF4 transcript levels. (B) Western blots of
protein lysates prepared from siRNA-treated SH-SY5Y cells
demonstrated that KD1 and KD2 reduced TCF4 levels whilst
GAPDH knockdown had no apparent effect. α-tubulin was used
as a loading control and for normalization. (C) LI-COR
quantitation of TCF4 protein levels in siRNA-treated cells. The
levels of TCF4 in each experiment were quantified and
normalized to α-tubulin as described previously [54,55]. In
agreement with the qPCR results, siRNA treatment reduced
TCF4 levels to approximately 20% of wild-type compared to
mock or GAPDH KD-treated cells.
doi: 10.1371/journal.pone.0073169.g001
Enrichment analysis of differentially expressed genes
in TCF4-depleted cells
Initial functional annotations associated with the 1204
differentially expressed genes in TCF4-knockdown cells were
found to span a range of biological functions that cluster
around the broad themes of metabolism, development and cell
signaling (Figure 2B). To ascertain whether any biological
functions were enriched in our high confidence gene list, we
selected all genes with Entrez gene IDs for enrichment
analysis. Of the 1204 genes that passed FDR correction of
0.01, 1031 had corresponding Entrez IDs (425 upregulated,
606 downregulated) and were statistically tested for GO
annotation enrichment using Database for Annotation,
Visualization and Integrated Discovery (DAVID) [26].
Functional annotations from up- and downregulated genes
were compared separately to a background list of genes
consisting of all expressed genes detected on the microarray.
This analysis identified several biological processes that were
significantly enriched (FDR 0.05) in TCF4 knockdown cells.
These terms included non-coding RNA metabolic processes,
apoptosis and regulation of NF-κB signaling (Table 2). Many of
the terms in this analysis are related to apoptosis. Importantly,
up- and down- regulated genes seemed to cluster by distinct
functional annotations (Table 2). For example, regulation of the
NF-κB and apoptotic signaling cascades and were significantly
enriched in the upregulated genes whereas annotations
relating to non-coding RNA metabolism, ribosome biogenesis
and protein folding were downregulated as a consequence of
TCF4 knockdown. Although not all the GO annotations listed in
the downregulated gene category passed multiple test
correction, they were nominally significant (P < 0.05) and
functionally linked.
To determine whether the apoptotic cell death pathway was
indeed activated in TCF4-depleted cells, we examined cell
viability and caspase activation after treatment with the
different siRNAs (Figure 3). TCF4-knockdown was associated
with significantly reduced cell viability compared to the control
groups (P = 2.8x10-16). Reduced cell viability was also
associated with increased caspase 3/7 activity (P = 1.3x10-3) in
TCF4-depleted cells (Figure 3A). Caspase-3 cleavage, which
occurs in cells undergoing apoptosis, was also detected by
western blotting in TCF4-depleted cells (Figure 3B).
Interestingly, cells treated with TCF4 KD2 showed more
evidence of apoptotic cell death and reduced viability
compared to TCF4 KD1. In control experiments, acute
staurosporine-treatment was associated with a robust increase
in apoptotic cell death in untransfected SH-SY5Y cells.
Although no gross differences in cellular morphology were
evident between siRNA-treated cells and controls, condensed
pyknotic nuclei were frequently observed in TCF4-depleted
cells (Figure S2).
Differential expression of genes in the TGF-β signaling
and EMT pathways in TCF4-knockdown cells
To refine the analysis of downstream gene expression
changes due to TCF4 knockdown, we utilized the MetaCoreTM
(GeneGo) analytical suite which provides a manually curated
database of “process networks” which detail more specific
Microarray Analysis of TCF4-Depleted Cells
PLOS ONE | www.plosone.org 3 August 2013 | Volume 8 | Issue 8 | e73169
Figure 2.  Overview of differentially expressed genes after TCF4 knockdown.  (A) Top 40 upregulated (upper panel) and
downregulated (lower panel) genes after FDR correction (0.01) ranked by fold change. (B) Functional characterization of all
differentially expressed genes (upregulated and downregulated) (FDR 0.01) using GOSLIM annotations. All annotation categories
representing less than 4% of the gene list were grouped and labeled as “other”.
doi: 10.1371/journal.pone.0073169.g002
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biological processes than GO annotations alone. In this
analysis, the full list of up- and downregulated genes with
Entrez IDs (1031 genes) were interrogated to reveal the
concerted function of the top differentially expressed genes.
This analysis identified a number of cellular processes in
TCF4-knockdown cells including TGF-β signaling, epithelial to
Table 1. qPCR validation of differentially expressed genes.
 Microarray qPCR
Gene Fold change P value Fold change P value
FAS 1.9 2.88E-05 2.9 3.58E-05
NTRK1 3.8 1.53E-05 4.1 3.58E-05
CASP8 3.0 1.38E-05 10.4 2.40E-03
NOTCH1 2.3 1.02E-04 2.9 6.03E-05
CASP1 15.7 6.13E-05 9.8 8.06E-03
IGF2 -5.2 1.52E-06 -4.2 2.51E-05
CDKN1C -2.4 2.36E-06 -2.3 1.02E-03
NEUROG2 -3.0 1.50E-05 -3.6 8.30E-07
BMP7 -3.7 1.34E-04 -2.4 5.46E-05
CDK6 -2.9 2.87E-07 -2.6 3.71E-06
Ten differentially expressed genes belonging to various functional categories were
chosen for qPCR validation. All the genes selected for validation had similar fold
changes by qPCR to that seen on the microarray. In both cases, the presented P
values represent the statistical significance between the pooled control (mock
treated, GAPDH KD) and TCF4 KD (KD1, KD2) groups.
mesenchymal transition (EMT), hedgehog signaling, apoptosis
and neurogenesis (Table 3). These data corroborate the
findings using DAVID, as process networks relating to
apoptosis (“Death Domain receptors and caspases in
apoptosis” and “Apoptosis stimulation by external signals”)
appeared in the list (Table 3).
Novel terms relating to particular signal transduction
pathways and developmental processes were identified using
MetaCore (Table 3). Specifically, three process networks
passed stringent FDR correction (FDR 0.05). In the signal
transduction category we identified process networks
associated with “TGF-β, GDF and activin signaling” and “BMP
and GDF signaling” to be over-represented. These terms refer
to signaling through the TGF-β superfamily of ligands [27].
TGF-β ligands operate through the activation of
transmembrane serine–threonine receptor kinases that
phosphorylate SMAD proteins to coordinate cell-type specific
gene expression. MetaCore analysis revealed that several
elements of the TGF-β signaling pathway where differentially
expressed after TCF4 knockdown. Differentially expressed
genes included two ligands of the TGF-β family (INHBA and
BMP7), the BMPR1A receptor, and several of the SMAD
proteins (SMAD2, SMAD4, SMAD7), demonstrating that each
level of the pathway was affected (Table 4).
The third term that remained statistically significant after FDR
correction was in the development category and relates to EMT
(Table 3). EMT is a developmental process whereby cells loose
their adhesive properties and become more motile. EMT is
Table 2. GO term enrichment analysis using DAVID.
GO annotation Genes P value
Corrected
P value
Upregulated genes (423 DAVID IDs)
1 GO:0043122~regulation of I-kappaB kinase/NF-kappaB cascade
CD40, TFG, TNFSF10, CASP1, TBK1, PLK2, TRIM38, NOD1, RHOC, HTR2B, WLS,
CARD8, SHISA5, TRADD, ZDHHC17 4.87E-07 8.50E-04
*
2 GO:0042981~regulation of apoptosis
MEF2C, LOC100289713, NGFRAP1, ARHGEF6, NOTCH1, SH3GLB1, TNFSF13B,
B4GALT1, TNFSF10, IDO1, BNIP3, APH1A, NOD1, ADAM17, CARD8, NGFR, SOCS3,
KALRN, TRADD, SOX9, MSX2, AEN, CADM1, BARD1, CASP4, CREB1, CD38, CASP1,
AKT1, CASP3, MCL1, JAK2, DPF2, TXNIP, FAS, TIA1, ANGPTL4, EYA1, YWHAZ,
NTRK1, SIRT1, BCL2L13
1.10E-05 1.92E-02*
3 GO:0009967~positive regulation of signaltransduction
CD40, BMPR1A, TFG, HIF1A, FKBP8, TNFSF10, CASP1, JAK2, TBK1, PLK2, TRIM38,
NOD1, HTR2B, ADAM17, JAG1, RHOC, WLS, RICTOR, SMAD4, SHISA5, TRADD,
ZDHHC17
1.18E-05 2.06E-02*
Downregulated genes (598 DAVID IDs)
1 GO:0034660~ncRNA metabolic process
CARS2, FARSB, POP7, TSEN2, WDR12, EXOSC1, DUS3L, TARSL2, ADAT2, RPL35A,
PDCD11, PIWIL1, IMP4, QTRTD1, TRMT10C, PUS3, EXOSC7, FTSJ1, MKI67IP, RPL7,
DIMT1
2.42E-05 4.14E-02*
2 GO:0022613~ribonucleoprotein complexbiogenesis
WDR12, GEMIN6, RRS1, EXOSC1, NCBP1, SURF6, RPL35A, TSR1, IMP4, PDCD11,
GEMIN5, EXOSC7, FTSJ1, NUFIP1, MRTO4, RPL7, BYSL, DIMT1 3.72E-05 6.37E-02
3 GO:0042254~ribosome biogenesis WDR12, RRS1, EXOSC1, SURF6, RPL35A, TSR1, IMP4, PDCD11, FTSJ1, EXOSC7,MRTO4, RPL7, BYSL, DIMT1 8.01E-05 1.37E-01
4 GO:0006457~protein folding BAG2, DNAJC12, SEC63, RUVBL2, FKBP7, GRPEL1, APCS, SACS, PFDN6, HSPBP1,PPIF, PPID, CCT6A, URI1, PPIH 7.06E-04 1.20
The Entrez Gene IDs of upregulated and downregulated genes were analyzed separately for biological process enrichment using DAVID. Enriched GO terms are ranked in
order of decreasing significance. The gene IDs in each GO category are listed alongside the corrected (FDR) and uncorrected P values. For clarity redundant terms were
removed. * Pass FDR correction of 0.05.
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Figure 3.  Knockdown of TCF4 induces apoptosis in SH-SY5Y cells.  Cells were treated with siRNAs for 72h after which cell
viability and caspase activity were measured (A). In addition to the siRNA treatment groups, untransfected SH-SY5Y cells were
exposed to staurosporine (1µM in DMSO) and vehicle for 3h to induce apoptosis. Knockdown of TCF4 leads to a significant
reduction in cell viability (P = 2.8x10-16, blue bars). Furthermore, TCF4-knockdown is also associated with an increase in caspase
3/7 activity compared to controls (P = 1.3x10-3, red bars). Although GAPDH knockdown is associated with reduced cell viability and
elevated caspase 3/7 activity compared to mock-treated cells, both assays showed statistical significant differences between the
control groups (mock and GAPDH) compared to TCF4-knockdown (TCF4 KD1 and KD2) supporting the microarray data. As
expected, staurosporine treatment also reduced cell viability and increased caspase 3/7 activity in untransfected cells. Western blot
analysis of caspase 3 processing after 72h knockdown shows that caspase 3 cleavage products are detected in siRNA treated cells
(B). β-actin was used as a loading control for all treatment groups.
doi: 10.1371/journal.pone.0073169.g003
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essential for neural tube formation and is thought to be a key
step regulating cancer cell metastasis [28]. Two important EMT
regulators, SNAI2 and DEC1 (BHLHB2 in Figure 2A) are
differentially expressed in response to TCF4 depletion. SNAI2
promotes EMT and is downregulated in TCF4-knockdown cells
whereas DEC1 is upregulated in TCF4-knockdown cells
(Figure 2A). It is also noteworthy that differentially expressed
genes associated to the EMT category are also of general
importance to development as they include elements of the
Notch, BMP and IGF signaling pathways.
RT-PCR was used to gain further support for the differential
expression of EMT genes in TCF4-depleted cells (Figure S3).
These data confirm the gene expression changes detected on
the microarray and show that in addition to SNAI2, SNA11 is
also downregulated in TCF4-depleted cells. Importantly,
expression of the closely related class I bHLH gene TCF3/E47
was unaltered in TCF4-depleted cells suggesting the
alterations in the EMT gene expression pathway occurred
independently of E47.
The IGF-signaling pathway also appears to be altered in
TCF4-depleted SH-SY5Y cells [29]. Specifically, IGF2 and
GRB14 are among the most significantly downregulated genes
whereas IGFBP5 and the genes encoding other IGF-binding
proteins are upregulated in our dataset (Figure 2 and Table 5).
These alterations in gene expression are also evident in
downstream elements of the IGF-signaling pathway and
include down-regulation of several kinases and adaptor
molecules such as AKT1 and RPS6KB1 that encodes the p70
ribosomal S6 kinase (Table 5).
Table 4. Gene expression changes associated with TGF-β
and Notch signaling pathways in TCF4-knockdown cells.
Gene FC P value Description
TGF-β signaling pathway
BMP7 -3.94 1.34E-04 BMP Ligand
BMPR1A 2.46 1.81E-05 Tyrosine kinase receptor (BMP)
SMAD2 -2.15 4.38E-04 R-SMAD (TGF/Nodal)
SMAD4 1.49 4.71E-04 co-SMAD
SMAD7 1.38 3.97E-04 I-SMAD
SMAD6 1.23 1.04E-02* I-SMAD
SMAD1 1.28 9.59E-03* R-SMAD (BMPR1)
NODAL -1.25 2.27E-04 Ligand (Nodal)
INHBA -2.38 2.68E-07 Ligand (Activin A)
LEFTY1 -2.81 3.37E-04 Ligand (Inhibitor of Nodal)
Notch signaling pathway
NOTCH1 2.40 1.02E-04 Ligand receptor
NOTCH2 -1.43 8.48E-03* Ligand receptor
JAG1 2.59 4.61E-04 Ligand receptor (inhibitor of Notch)
ADAM17 1.44 3.83E-04 metallopeptidase (Notch-cleavage)
APH1A 1.64 1.57E-04 γ-secretase complex (Notch-cleavage)
HES1 1.65 4.67E-05 Notch effector
HES7 -1.54 6.40E-03* Notch effector
Gene expression changes in manually curated signaling pathways in TCF4-
knockdown cells. The data are presented as statistically significant (FDR 0.01)
gene expression changes (fold change) for the genes in the TGF-β and Notch
signaling pathways. * Pass FDR correction of 0.05.
Table 3. Process network enrichment in MetaCore.
Category Process Network Genes P value FDR
Signal Transduction TGF-β, GDF and Activin signaling PTPRK, PTGER2, CREB1, GATA3, CCND1, INHBA, SMAD4, FOS, SP1, SMAD2, HIF1A,ATF2, SMAD7, LEFTY1, MYC, TOB1, NOTCH1, CDK6 3.54E-04 0.044
*
Signal Transduction BMP and GDF signaling CREB1, MSX2, BMPR1A, AKT1, BMP7, SMAD4, TLE1, ATF2, SMAD7, MYC, NODAL,SOX9, TOB1, CDK6 8.02E-04 0.044
*
Development Regulation of epithelial-to-mesenchymal transition
NOTCH1, CREB1, ACTA2, JAK2, BMP7, TRADD, SMAD4, FOS, SP1, SMAD2, HIF1A,
ATF2, ABBP1, JAG1, SMAD7, ADAM17, SNAI2, IGF2, TJP1, SOX9 8.38E-04 0.044
*
Development Regulation of telomere length TINF2, MAX, TEP1, SP1, HNRNPC, MYC, PTGES3, CDK6 5.35E-03 0.190
Development Hedgehog signaling NOTCH1, CREB1, HESX1, CCND1, SIRT1, INHBA, AKT1, BMP7, RBX1, SMAD4,ASCL1, ZIC1, SP1, ROCK2, PBX1. CDKN1C, HES1, JAG1, MYC, ADAM17, SOX9 6.06E-03 0.190
Apoptosis Death Domain receptors andcaspases in apoptosis
NGFRAP1, NGFR, TRADD, CD40, TIMP3, TNFSF10, CASP1, TRAF4, NOD1, PDCD5,
CASP3, BIRC8, FAS, CASP4, CARD8 7.26E-03 0.190
Apoptosis Apoptosis stimulation by externalsignals
NGFRAP1, JAK2, BID, NGFR, NTRK1, TRADD, SMAD4, TNFSF10, FOS, SMAD2,
ADAM17, CASP3, FAS, BID 9.66E-03 0.217
Development Neurogenesis in general NOTCH1, CREB1, HESX1, GFRA3, INHBA, RCAN1, ASCL1, ZIC1, PBX1, NEUROG2,HES1, JAG1, ADAM17, CHRM3, MEF2C, SERPINI1 1.24E-02 0.237
DNA damage Checkpoint YWHAQ, CCND1, TLK2, BRIP1, CCND3, RUVBL2, ATF2, ATF3, RAD1, BARD1, MYC,YWHAZ, CDK6 1.51E-02 0.237
Cardiac
development BMP and TGF-β signaling
MSX2, ISL1, BMPR1A, BMP7, SMAD4, PDLIM3, MYH7, SMAD2, SMAD7, NODAL,
SNAI2, SOX9, MEF2C 1.51E-02 0.237
The Entrez gene IDs derived from the high-confidence list of 1031 differentially expressed genes in TCF4-knockdown cells were analyzed for enrichment using MetaCoreTM.
Each term is presented with its functional category, network and corresponding P value. * Pass FDR correction of 0.05.
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Altered expression of neurogenic and neurological
disease genes in TCF4-depleted cells
One of the initial aims of this study was to identify gene
expression changes in neurodevelopmental genes.
Accordingly, we found that the proneural genes ASCL1 and
NEUROG2 were downregulated in TCF4-depleted cells (Figure
2A). In addition to the proneural genes, a number of genes
implicated in rare Mendelian forms of mental retardation were
differentially expressed in TCF4 knockdown cells (Table 6).
Interestingly, these differentially expressed genes are mutated
in disorders that resemble Rett syndrome and have phenotypic
similarities to PTHS. For example, MEF2C is found in the top
40 most significantly upregulated genes in TCF4-knockdown
cells (Figure 2A). Furthermore, UBE3A (mutated in AS) is
downregulated in TCF4 knockdown cells whereas the MWS
gene and EMT regulator ZEB2, is upregulated (Table 6).
Discussion
It is now well established that rare, highly penetrant TCF4
alleles are associated with neurodevelopmental phenotypes
whereas common variants are associated with disorders such
as schizophrenia [6–8,13,14]. Recent cognitive and imaging
studies have also shown that TCF4 is important for normal
brain function [1,15]. However, knowledge of TCF4-regulated
genes and pathways in the brain is comparatively sparse.
Table 5. Gene expression changes associated with the IGF
signaling pathway in TCF4-knockdown cells.
Gene Fold change P value Description
IGF2 -5.22235 1.52E-06 IGF ligand
IGFBP5 4.90659 2.35E-05 IGF carrier protein
IGFBP3 1.28834 1.17E-02* IGF carrier protein
IGFBP4 2.59348 3.09E-03* IGF carrier protein
IGFBPL1 -1.43755 8.52E-05  
GRB14 -3.08126 1.79E-05 Receptor-bound protein (inhibitor)
GRB7 -1.22578 1.95E-04 Receptor-bound protein (inhibitor)
PIK3CG -1.75377 9.67E-03* Signal transduction (kinase)
PIK3CA 1.58222 6.16E-04* Signal transduction (kinase)
PIK3C2B -1.45293 5.42E-03* Signal transduction (kinase)
PIK3CD -1.30542 7.37E-03* Signal transduction (kinase)
PDPK1 (PDK1) -1.98747 8.88E-05 AKT inhibition (kinase)
AKT1 1.36045 3.53E-04 Signal transduction (kinase)
YWHAG -1.9787 7.64E-05 Regulatory co-factor
YWHAZ 1.2674 3.63E-04 Regulatory co-factor
FOXO1A 1.6064 3.75E-03* Transcription factor
FOXO3B -1.72656 3.65E-03* Transcription factor
RPS6KB1 (S6K1) -1.2898 3.83E-03* Ribosomal subunit kinase
RPS6KC1 1.78394 4.15E-03* Ribosomal subunit kinase
RPS6KA3 1.47367 6.83E-03* Ribosomal subunit kinase
RPS6KA1 -1.32884 2.57E-03* Ribosomal subunit kinase
Gene expression changes in the manually curated IGF signaling pathway in TCF4-
knockdown cells. The data are presented as statistically significant (FDR 0.01)
gene expression changes sorted by fold change for the genes in the IGF signaling
pathway [29]. * Pass FDR correction of 0.05.
Using genome-wide transcriptional profiling of SH-SY5Y cells
where TCF4 was knocked down with siRNAs, we demonstrate
that TCF4 reduction affects the expression of genes involved in
cell signaling, cell survival and neurodevelopment. By
deconstructing the top gene expression changes, we also show
that genes controlling apoptosis tend to be upregulated whilst
genes that support processes involving non-coding RNA
metabolism are downregulated. Process network enrichment
analysis also suggests that the TGF-β, Notch and IGF signaling
pathways may converge on the EMT pathway in TCF4-
depleted cells.
GO enrichment analysis implicates TCF4 in apoptosis
and non-coding RNA metabolism
We used several bioinformatics tools to search for processes
and pathways that may be altered in TCF4-depleted cells.
Initial results from GO term enrichment analysis using DAVID
showed that apoptosis and NF-κB signaling were statistically
significant processes among the upregulated genes. Shared
terms in GO categories between NF-κB signaling and cell
death categories show that many of the genes in each pathway
are the same, indicating some degree of convergence between
NF-κB signaling and apoptosis (Table 2). In neurons, NF-κB
regulates the expression of genes participating in seemingly
diverse aspects of neurodevelopment, learning and memory
[30]. NF-κB signaling has also been implicated in enhancing
neuronal apoptosis associated with neurodegenerative
disease, brain injury and inflammatory conditions [31]. Similarly
in neurons, caspase activation is known to be important for
axon pruning and synapse elimination and can mediate some
of the chronic neuropathological events associated with brain
injury or neurodegeneration [32]. Since acute knockdown of
TCF4 over a period of 72h reduced cell viability and increased
caspase 3/7 activity, up-regulation of some caspases and
components of the NF-κB pathway in TCF4-depleted cells may
induce cell death (Figure 3). It is therefore possible that TCF4
may regulate the expression of some caspase genes and other
components of the pro-apoptotic signaling pathway in SH-
SY5Y cells.
Table 6. Altered expression of several mental retardation
(MR) genes in TCF4-knockdown cells.
Gene Disease OMIM InheritanceFC P value Reference
TCF4 PTHS 610954 AD -3.10 2.02 E-05 [9]
MEF2C Syndromic MR 613443 AD 3.73 1.37 E-05 [50]
UBE3A AS 105830 imprinted -1.39 1.56 E-03* [59]
ZEB2 MWS 235730 AD 1.48 3.60 E-03* [60]
FMR1 Fragile Xsyndrome 300624 X-linked 1.94 1.51 E-02
** [61]
Data presented are the fold change and the corrected P value (FDR 0.01) derived
from the microarray. Pass FDR correction of 0.05, pass FDR correction of 0.1.
Abbreviations: PTHS, Pitt-Hopkins syndrome; AS, Angelman Syndrome; MWS,
Mowat-Wilson syndrome.
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TCF4-knockdown affects genes in the TGF-β signaling
pathway
To gain further insight in to TCF4-regulated pathways, we
used MetaCore to identify network processes that were altered
in TCF4-depleted cells. Enrichment analysis on the top 1031
differentially expressed genes, demonstrated that several
components of the TGF-β signaling pathway are affected.
Specifically, we found robust down-regulation of the TGF-β
superfamily ligands (BMP7, NODAL, LEFTY1 and INHBA) and
altered expression of several downstream components of the
TGF-β signaling cascade including BMPR1A, and some of the
SMAD transcription factors (Table 4). TGF-β signaling
regulates many aspects of cell proliferation, differentiation,
migration and apoptosis [27]. In the nervous system, TGF-β
signaling regulates neural crest formation and in also required
for neurogenesis, neurite outgrowth and synaptogenesis
[33,34]. Interestingly, Bmp7 regulates the survival and
proliferation of neural progenitor cells in the developing
neocortex of mice and maintains Ngn2 (the murine orthologue
of NEUROG2) in ventricular and subventricular zones of the
cortex [35]. Notably, both BMP7 (FC, -3.93) and NEUROG2
(FC, -3.10) are robustly downregulated in TCF4-depleted cells
suggesting that TCF4 may coordinately regulate each gene
(Figure 2A).
TCF4-knockdown affects EMT regulators
In addition to driving developmental programs, TGF-β
signaling is also involved in EMT.
Process network enrichment identified genes in the EMT
pathway to be differentially expressed in TCF4-knockdown
cells compared to controls (Table 4). This pathway governs the
transition between epithelial and mesenchymal phenotypes
known to be important during development and in cancer
metastasis [36]. TGF-β activates SMADs 3 and 4 to transcribe
SNAI1 that represses expression of critical epithelial cell genes
such as CDH1 (E-cadherin, a commonly used molecular
marker of the epithelial phenotype) allowing activated cells to
switch to the mesenchymal phenotype [27]. In addition to
components of the TGF-β signaling pathway, the EMT
regulators SNAI1/2 and DEC1 (BHLHB2 on the array) were
differentially expressed in TCF4-knockdown cells (Figure 2A
and Figure S3). SNAI1 and 2 are transcriptional repressors that
bind to E-boxes in the promoter regions of genes including
Cdh1 [37]. Similarly, DEC1 is another transcriptional repressor
that regulates EMT in pancreatic cancer cells in response to
TGF-β stimulation [38]. Our data are therefore consistent with
findings in other cell types showing that the E-proteins TCF4
and E47 are involved in EMT [39–41].
Gene expression changes in the IGF signaling pathway
In addition to changes in gene expression associated with
the TGF-β and Nodal signaling, TCF4-knockdown also alters
the expression of components of the IGF signaling pathways
(Table 5). TCF4-knockdown is associated with a 5.2 fold down-
regulation of IGF2 and up-regulation of the genes encoding
IGF binding proteins, IGFBP3, -4 and -5 (Figure 2A and Table
5). In the brain, IGF2 is required for memory consolidation and
enhancement [42], adult hippocampal neurogenesis [43],
synapse formation and dendritic spine maturation [44]. Since
IGF2 has a role in learning and memory and PTHS patients
have profound intellectual disability [45], TCF4 regulation of
IGF2 expression may be a determinant of cognitive
dysfunction. IGF1 treatment has been shown to reverse some
of the neurophysiological abnormalities in a mouse model of
Rett Syndrome lacking methyl CpG-binding protein 2 (Mecp2
[46]). Because IGF1 and IGF2 activate the same receptor,
IGF2 may have some utility in reversing some of the cognitive
deficits in PTHS patients. Another component of the IGF
pathway RPS6KB1 (encoding a member of the ribosomal
protein S6 kinase family), is also downregulated in TCF4-
depleted cells (Table 5). RPS6KB1 may be particularly
important in the context of neurodevelopment because genetic
ablation of this gene rescues multiple physiological and
behavioural phenotypes in a mouse model of fragile X
syndrome, caused by aberrant synaptic translation [47].
Altered expression of neurodevelopmental genes in
TCF4-knockdown cells
ASCL1 and NEUROG2 are important neurogenic bHLH
transcription factors that interact directly with TCF4 and appear
among the top downregulated genes in TCF-depleted cells
(Figure 2A and Table 2 respectively). Since both of these
proneural genes are downregulated, this may indicate that as
well as regulating proneural activity through protein: protein
interactions, TCF4 may also regulate proneural gene
expression. In addition to ASCL1 and NEUROG2, other
neurodevelopmental transcriptional regulators such as, MEF2C
(syndromic mental retardation) and ZEB2 (MWS) were also
differentially expressed in TCF4-depleted cells.
PTHS, MWS and AS are sometimes classified as Rett-like
syndromes because of their similar clinical presentation and
genetics [9,48]. Furthermore, haploinsufficiency of MEF2C also
results in a form of severe mental retardation, with absent
speech, hypotonia and epilepsy [49,50]. Importantly, we found
that the genes for each of these phenotypically similar
disorders (MEF2C, ZEB2 and UBE3A) were differentially
expressed in TCF4-depleted cells (Table 6). From a
mechanistic perspective, TCF4, ZEB2 and MEF2C can all
regulate gene expression at E-boxes in the promoter regions of
certain genes [51,52]. These data, allied with the phenotypic
overlap between these disorders, suggest that each of these
genes may participate in a similar neurodevelopmental
transcriptional pathway. Thus, alterations in the activity or
levels of TCF4 as seen in PTHS, autism and possibly
schizophrenia, may be associated with dysregulation of several
transcription factors that control neurodevelopmental gene
expression programs at E-box containing promoters.
In summary, microarray analysis of SH-SY5Y cells where
TCF4 has been acutely knocked down with siRNAs identifies
gene expression changes in pathways associated with
apoptosis, signaling, EMT and neurodevelopment. These data
provide an important insight in to the cellular processes that are
regulated by TCF4. Our data also suggest a novel shared
mechanism in a subset of neurodevelopmental disorders that
regulate aspects of normal brain function and may also
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contribute to the molecular pathology of common diseases
such as autism and schizophrenia.
Methods
RNA interference and transfection
27 mer RNA oligonucleotide duplexes were designed using
predictive algorithms (siDESIGN Center, http://
www.thermoscientificbio.com/design-center/; siMAXTM Design
Tool, http://www.eurofinsdna.com) and were selected for their
predicted efficacy scores and homology to regions of interest.
Two duplexes (KD1 (exon 12), 5’-
GGGACAGACAGUAUAAUGGCAAAUAGA; KD2 (exon19), 5’-
AUAAUGACGAUGAGGACCUGACACCAG) were designed to
target constitutive exons found in all the published human
TCF4 transcripts [19]. The GAPDH siRNA 5’-
CGGAGUCAACGGAUUUGGUCGUAUUGG was used in
control experiments to identify transcripts that were altered by
RNA interference having minimal off-target affects. siRNAs
(Eurofins MWG Operon) were stored as a 50mM stock in
siMAX Universal Buffer (30mM HEPES, 100mM KCl, 1mM
MgCl2; pH 7.3) at -80°C.
SH-SY5Y (American Type Culture Collection, ATCC) cells
were cultured in Dulbecco’s modified Eagle medium (DMEM,
Invitrogen) supplemented with 10% (v/v) foetal calf serum
(FCS, PAA laboratories) without antibiotics. 24h after seeding,
cells were transfected with the different siRNA duplexes (TCF4
KD1 and KD2, GAPDH or mock) using Lipofectamine®
RNAiMAX (Invitrogen) at a final concentration of 10nM. 48h
after the first transfection the cells were re-transfected using
the same conditions. The following day (72h after the first
transfection), RNA and protein were prepared from each
experimental condition. Each transfection was performed in
quadruplicate and three biological replicates were used for
gene expression analysis whilst the remaining sample was
used for western blotting.
Western blotting
For quantitation of protein levels after siRNA treatment,
transfected SH-SY5Y cells were lysed in RIPA buffer and the
resulting lysates were clarified by centrifugation. 10µg of each
lysate was separated on a 12% gel polyacrylamide gel and
transferred to nitrocellulose as described previously [53].
Membranes were blocked overnight in blocking buffer (5%
(w/v) milk powder in Tris-buffered saline containing Tween-20
(TBST)) and then incubated with anti-TCF4 (Abnova) and anti-
α-tubulin antibodies (12G10, Developmental Studies
Hybridoma Bank, The University of Iowa) diluted in blocking
buffer. After extensive washing in TBST, blots were incubated
with the appropriate secondary antibody prior to imaging on a
LI-COR Odyssey infrared scanner. Proteins levels were
quantified using the Odyssey software version 2.1 as described
previously [54,55].
Quantitative and reverse transcriptase PCR (qPCR and
RT-PCR)
RNA was extracted from siRNA-treated cells using RNeasy
Plus Mini Kits (QIAGEN) according to the manufacturer’s
instructions. Total RNA was treated with Ambion® TURBO
DNA-free™ DNase I (Invitrogen) before being converted to
cDNA using the ProtoScript® M-MuLV First Strand cDNA
Synthesis Kit (NEB). Triplicate 25µl qPCR reactions were
prepared on a Corbett robot (Corbett Robotics CAS1200/
QIAGEN) using 10ng of cDNA as a template, SensiMixTM
SYBR No-ROX (Bioline) and an optimized concentration of
gene-specific primers. qPCR was then performed on a Qiagen
Rotor-Gene 6000 (Corbett Robotics/QIAGEN). GAPDH, TCF4
and 18S primer efficiencies were all optimized prior to use on
experimental samples. Gene expression was quantified using
the ΔCT method and 18S rRNA as an internal control. Primer
sequences are listed in Table S1A.
TaqMan® gene expression assays were used to validate
gene expression changes (NOTCH1, FAS, CASP8, CASP1,
NTRK1, NEUROG2, CDK6, BMP7, IGF2 and CDKN1C) after
knockdown using pre-optimized reagents (Table S1B). Briefly,
1-10ng of cDNA was used as template in 20µl reactions with
the TaqMan® Fast Advanced Master Mix depending on
transcript abundance (Applied Biosystems/Life technologies).
All samples were run in triplicate according to the Fast
Advanced Master Mix protocol using the ABI 7900HT Fast
Real-Time PCR System (Applied Biosystems/Life
technologies). Results were then analyzed on the RQ Manager
1.2 (Applied Biosystems/Life technologies). All genes were
normalized to 18S rRNA using the ΔCT method. To calculate
fold change, the relative transcript abundance from mock and
GAPDH KD samples were pooled and compared to the values
of pooled KD1 and KD2 samples. A two-tailed t-test was
performed on these two groups to determine statistical
significance.
For semi-quantitative RT-PCR, 10ng of cDNA was amplified
(30 cycles) in a 25µl reaction with REDTaq® DNA Polymerase
according to manufacturer’s instructions (Sigma). The
sequences of the gene-specific primer pairs are listed in Table
S1C. 20µl of the PCR reaction was separated on a 2.5%
agarose gel containing ethidium bromide. PCR products were
imaged with a GelDoc-It® TS Imaging System (UVP).
Toray Microarray
Three biological replicates from four treatment groups (TCF4
KD1and KD2, GAPDH KD and mock) were sent for microarray
analysis (Central Biotechnology Services, School of Medicine,
Cardiff University). Briefly, the RNA concentration and quality
was assessed on a RNA Nano Chip using the Agilent 2100
Bioanalyser (Agilent Technologies). RNA was labeled,
fragmented then hybridized to 3D-gene Human Oligo chip 25 k
(Toray Industries Inc., Japan). Chips were scanned three times
at different intensities and normalized. The resulting signal
intensity data was then analyzed in-house. Data was imported
into Partek Genomics Suite 6.6 (Partek Inc.) and analyzed. As
there were only three replicates in each group, probe sets with
more than one missing value in any group were removed from
the analysis. A one-way ANOVA comparing control (mock and
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GAPDH) and TCF4 knockdown (KD1, KD2) groups was then
performed to identify differentially expressed genes. A false
discovery rate (FDR) was used to correct for multiple testing
(FDR < 0.01, 1204 differentially expressed genes; FDR < 0.05,
5374 differentially expressed genes). The data discussed in
this publication have been deposited in NCBI’s Gene
Expression Omnibus [56] and are accessible through GEO
Series accession number GSE48367 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48367).
Enrichment Analysis
The Entrez Gene IDs from the high confidence (FDR 0.01,
1031 IDs) gene list was used as the initial dataset for
enrichment analysis. In addition, a background list consisting of
Entrez Gene IDs from all genes detected by the microarray
was also generated (18966 IDs). Biological process GO term
enrichment (GOTERM_BP_FAT) was performed using DAVID
v 6.7 [26]. 425 upregulated and 606 downregulated genes were
analyzed separately using the same background list. Process
Network term enrichment was performed using MetaCoreTM
(GeneGo, Thomson Reuters). Here, the full FDR corrected list
(1031 IDs) was uploaded and compared to the background list
of genes. An FDR cut off of 0.05 was used to determine
significant enrichment from both analyses. Manually curated
pathways were annotated using the Kyoto Encyclopedia of
Genes and Genomes (KEGG, http://www.genome.jp/kegg/)
Pathways and WikiGenes (http://www.wikigenes.org) web
resources [57,58]. Please note that we have used the HGNC
(Human Genome Nomenclature Committee) nomenclature for
each gene but provide common synonyms for some of the
genes that were followed up in this study.
Cell viability and caspase assays
SH-SY5Y cells were plated in 96 well plates and treated with
the appropriate siRNAs for 72h as described above. Cell
viability and caspase 3/7 activation were measured in the same
plate using the CellTiter-Fluor™ Cell Viability (Promega) and
the Caspase-Glo® 3/7 (Promega) assays. Staurosporine-
treated (1µM in DMSO, 3h at 37°C) SH-SY5Y cells were used
as a positive control for each assay. Cell viability was
measured in 24 replicates of each condition whereas 12
biological replicates were used to assay caspase 3/7 activity.
The data were normalized to the levels in the mock-transfected
cells, nominally 100%, and represented as the mean and
standard error. T-tests were used to compare treatment
groups. In addition to the microplate assays, caspase 3
cleavage was assessed by western blotting. After treatment,
dead cells were collected from the media by centrifugation and
lysed with the remaining live cells. 15μg of each lysate was
used for western blotting with a caspase 3 (#9662, Cell
Signaling) and β-actin (AC-15, Sigma) antibodies.
Immunocytochemistry
SH-SY5Y cells were processed for immunocytochemistry as
described previously [53,54]. Briefly, siRNA-treated cells grown
on coverslips were fixed in 4% (v/v) formaldehyde,
permeabilised with 0.01% (v/v) Triton-X100 and blocked with
10% (v/v) foetal calf serum. Cells were labeled at room
temperature with Alexa Fluor 488 phalloidin (165nM,
Invitrogen), Hoechst (1µg/ml, Invitrogen) and an anti-TCF4
polyclonal antibody (Covalab, UK) for 1h followed by Alexa
Fluor 546 goat anti-rabbit IgG (Invitrogen) for a further 30min.
After washing in PBS, coverslips were mounted in Aqua-Poly/
Mount (Polysciences, Inc.) and images were captured on a
Leica SP2 confocal microscope using a 63X oil immersion
objective lens. Images were assembled using Adobe
Photoshop CS4 and only adjusted for brightness and contrast.
Supporting Information
Figure S1.  Hierarchical clustering of the top differentially
expressed genes. The top 1204 differentially expressed genes
(FDR 0.01) cluster by treatment group as evident from the
dendrogram to left of the heatmap. Samples from the control
treatments (mock and GAPDH KD) and TCF4 KD treatment
(KD1 and KD2) are shown to cluster into defined groups (white
and black respectively). The top section of the heat map
displays differential expression relative to controls: up-
regulated genes are shown in red while down-regulated genes
are coloured blue.
(EPS)
Figure S2.  Cellular imaging of siRNA-treated SH-SY5Y
cells. SH-SY5Y cells were treated with siRNAs for 72h as
described above. Fixed cells were stained with Alexa Fluor 488
phalloidin (F-actin), Hoescht-33342 (nuclei) and with an anti-
TCF4 polyclonal antibody. Although there is a marked
reduction in TCF4 immunoreactivity in TCF4 KD cells, no
apparent morphological differences are observed between
treatment groups after 3 days knockdown. A few condensed
pyknotic nuclei, indicative of apoptosis were observed after
TCF4 KD treatment (arrow heads).
(TIF)
Figure S3.  Semi-quantitative RT-PCR analysis of EMT-
regulating transcription factors in TCF4-knockdown cells.
RT-PCR was used to confirm differential expression of several
transcription factors that drive EMT. SNAI1 and SNAI2
transcripts are down-regulated in TCF4-knockdown cells
whereas BHLHE40 (DEC1) and MEF2C transcripts are up-
regulated. These data also show that TCF3/E47 transcripts,
which encode a paralogue of TCF4 that is required for EMT,
are unaltered in TCF4-depleted cells. Note that alterations in
SNAI1 were not evident on the microarray possibly due to its
low expression in SH-SY5Y cells.
(TIF)
Table S1.  Primer sequences and TaqMan probes.
(A) qPCR primers used for knockdown quantification (SYBR
Green).
(B) TaqMan probe IDs used for microarray validation.
(C) Primers used for semi-quantitative RT-PCR.
(DOCX)
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